EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro



RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro



Plos One 8(5): E63153-E63153



The osteolytic nature of bone metastasis results from a tumor-driven increased bone resorption. Bone remodeling is orchestrated by the molecular triad RANK-RANKL-OPG. This process is dysregulated in bone metastases, mostly via induction of RANKL by tumor-derived factors. These factors increase expression of RANKL, which induce osteoclast formation, function, and survival, thereby increasing bone resorption. RANK is unexpectedly expressed by cancer cells, and the activation of RANKL-RANK pathway correlates with an increased invasive phenotype. To investigate the interaction between RANK expression in human breast and prostate cancer cells and their pro-metastatic phenotype we analyzed the activation of RANKL-RANK pathway and its effects on cell migration, invasion, gene expression in vitro, and osteolysis-inducing ability in vivo. RANKL activates kinase signaling pathways, stimulates cell migration, increases cell invasion, and up-regulates MMP-1 expression. In vivo, MMP-1 knockdown resulted in smaller x-ray osteolytic lesions and osteoclastogenesis, and decreased tumor burden. Therefore, RANKL inhibition in bone metastatic disease may decrease the levels of the osteoclastogenesis inducer MMP-1, contributing to a better clinical outcome.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333215

Download citation: RISBibTeXText

PMID: 23696795

DOI: 10.1371/journal.pone.0063153



Related references

RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World Journal of Urology, 2017

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2): 289-298, 2006

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews 15(6): 457-475, 2004

The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Reviews 25(4): 541-549, 2006

Regulation of OPG/RANK/RANKL by PTHrP peptides in human prostate cancer cells. Journal of Bone & Mineral Research 17(Suppl 1): S286, September, 2002

Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells. Biochemical and Biophysical Research Communications 408(3): 411-416, 2011

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Research 33(1): 199-206, 2013

The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications. Bulletin du Cancer 98(7): 837-846, 2011

A Comparison of Ki67, Syndecan-1 (CD138), and Molecular RANK, RANKL, and OPG Triad Expression in Odontogenic Keratocyts, Unicystic Ameloblastoma, and Dentigerous Cysts. Disease Markers 2018: 7048531-7048531, 2018

RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells. Journal of Bone Oncology 2(3): 116-122, 2013

Expression of Receptor Activator of Nuclear Factor kB Ligand (RANKL) in Breast Cancer Is Inversely Correlated With the Triple-Negative Phenotype and Brain Metastatic Potential. American Journal of Clinical Pathology 138(Suppl 2): A025-A025, 2012

RANK/RANKL expression in prostate cancer. International Journal of Surgery Case Reports 30: 106-107, 2016

Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Research 67(13): 6183-6191, 2007

RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends in Endocrinology and Metabolism: Tem 22(5): 188-194, 2011

Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells. Experimental Oncology 37(3): 181-186, 2016